Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥6.3bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥13.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥6.4bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income−¥111m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥89m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥157m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥108m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥95m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥195m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥94m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥182m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥48m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥185m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥42m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥10.6bnat 2024-09-30Cons.Assets
Total assets¥9.8bnat 2024-03-31Cons.Assets
Total assets¥10.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.8bnat 2024-09-30Cons.Liabilities
Total liabilities¥3.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥5.8bnat 2024-09-30Cons.Net assets
Net assets / equity¥6.0bnat 2024-03-31Cons.Net assets
Net assets / equity¥6.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.3bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥2.5bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥2.2bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.5bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥421m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥392m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥366m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥175m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥281m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥129m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥379m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥343m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥47m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-10.972024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.242023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥2.872023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio53.5%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio60.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥114m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥806m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥803m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥189m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥45,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥192m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥3m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥108m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥981m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥978m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥27m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥628,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥223m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥4m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥196m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任監査法人トーマツ
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)城戸 昭博
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)甲斐 貴志
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration6377299000JPY
Net sales (5-year summary)CurrentYTDDuration6311881000JPY
Net sales (5-year summary)Prior1YearDuration13083458000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration94791000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration-156532000JPY
Ordinary income loss (5-year summary)Prior1YearDuration108326000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration48464000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration-182259000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration4085000JPY
Comprehensive income (5-year summary)Prior1YTDDuration70607000JPY
Comprehensive income (5-year summary)CurrentYTDDuration-200700000JPY
Comprehensive income (5-year summary)Prior1YearDuration27942000JPY
Net assets (5-year summary)Prior1QuarterInstant6119746000JPY
Net assets (5-year summary)CurrentQuarterInstant5753984000JPY
Net assets (5-year summary)Prior1YearInstant5998464000JPY
Total assets (5-year summary)Prior1QuarterInstant10482478000JPY
Total assets (5-year summary)CurrentQuarterInstant10575344000JPY
Total assets (5-year summary)Prior1YearInstant9810999000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration2.87
Basic earnings loss per share (5-year summary)CurrentYTDDuration-10.97
Basic earnings loss per share (5-year summary)Prior1YearDuration0.24
Diluted earnings per share (5-year summary)Prior1YTDDuration-
Diluted earnings per share (5-year summary)CurrentYTDDuration-
Diluted earnings per share (5-year summary)Prior1YearDuration-
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.574
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.535
Equity to asset ratio (5-year summary)Prior1YearInstant0.601
Net cash provided by used in operating activities (5-year summary)Prior1YTDDuration-365546000JPY
Net cash provided by used in operating activities (5-year summary)CurrentYTDDuration-421145000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration-392453000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YTDDuration-129107000JPY
Net cash provided by used in investing activities (5-year summary)CurrentYTDDuration-174666000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration-280928000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YTDDuration-46774000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYTDDuration378836000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration-342689000JPY
Cash and cash equivalents (5-year summary)Prior1QuarterInstant2920760000JPY
Cash and cash equivalents (5-year summary)CurrentQuarterInstant2244975000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant2466101000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember16999141
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember16999141
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant16999141
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant16999141
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember441211
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.0264

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass